Elliot Heath System announced today that Medical Director of Elliot Acute Urological Services, Dr. Christopher Girasole, is the first provider in New Hampshire to offer Aquablation therapy for the treatment of lower urinary tract symptoms in men. Aquablation treats benign prostatic hyperplasia (BPH), which is a non-cancerous condition where the prostate has grown to be larger than normal. One in two men ages 51 to 60 have BPH, and the incidence increases every decade of life. If left untreated, BPH can cause significant health problems. The surgery is currently only available from Manchester Urology Associates in the state of New Hampshire.
“We are proud to be the first in New Hampshire to offer Aquablation for men. Other surgical treatments often force men to face irreversible complications to achieve a high degree of symptom relief. This surgery with provides relief without compromise,” said Dr. Christopher Girasole, Medical Director of the Elliot Acute Urological Services. “Aquablation therapy uses the power of water delivered with robotic precision to provide long-lasting symptom relief with low rates of irreversible complications.” 1,2
Dr. Girasole has already completed several Aquablation surgeries, all with successful outcomes. J.L., one of Dr. Girasole’s first patients, said, “I am extremely pleased with the Aquablation therapy that I received. I would absolutely recommend this procedure to anyone who might need it. I wish Aquablation therapy was available 25 years ago, instead of the ‘old school’ method, which really concerned me. I would have had this operation done sooner. I feel a great relief, and I am not concerned about long-term side effects because I chose Aquablation instead of other procedures that are available for treatment.”
Aquablation therapy is performed by the AquaBeam Robotic System, the first FDA-cleared, surgical robot utilizing automated tissue resection or the treatment of lower urinary tract symptoms due to BPH. It combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience.
For more information about Aquablation and to find out if it is the right choice in therapy, contact Manchester Urology Associates, by calling 603-669-9200.
About Elliot Health System, a member of SolutionHealth - Elliot Health System is a non-profit organization serving the healthcare needs of the community since 1890. The largest provider of comprehensive healthcare services in Southern New Hampshire, Elliot Hospital, a 296-bed acute care facility and the first community hospital in the state, serves as the cornerstone of the health system. Elliot is home to Manchester’s designated Regional Trauma Center, Elliot Breast Health Center, Elliot Urgent Care, a Level 3 Newborn Intensive Care Unit, Elliot Medical Group, Solinsky Center for Cancer Care at The Elliot, Elliot Senior Health Center, Visiting Nurse Association of Manchester and Southern New Hampshire, 1-Day Surgery Center, Elliot Memory & Mobility Center, NH Arthritis Center, Elliot Retail Pharmacy, Elliot Medical Centers in Bedford, Londonderry, Hooksett, and The Elliot at River’s Edge.
About PROCEPT BioRobotics Corporation - PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on BPH, the AquaBeam Robotic System delivering Aquablation therapy is the first FDA-cleared, surgical robot utilizing automated tissue resection for the treatment of lower urinary tract symptoms due to BPH. Aquablation therapy combines real-time, multi-dimensional imaging, automated robotic technology, and heat-free waterjet ablation technology for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size, or surgeon experience. For more information visit https://www.procept-biorobotics.com.
References: 1. Gilling, P, et al. Three-Year Outcomes after Aquablation Therapy Compared to TURP: Results from a Blinded Randomized Trial. Can J Urol. 2020 Feb;27(1):10072-10079. 2. Desai, M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol. 2020 Apr;27(2):10147-10153.